Last reviewed · How we verify
Isatuximab, bortezomib, lenalidomide, dexamethason
At a glance
| Generic name | Isatuximab, bortezomib, lenalidomide, dexamethason |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Isa-VRD in TIE HRMM (PHASE4)
- REST - Replacing Steroids in the Transplant Ineligble (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: